NCT02537613 2026-04-01
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT04277637 2026-03-27
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
BeOne Medicines
Phase 1 Active not recruiting
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06291220 2026-01-08
453 Ph1 CLL
AbbVie
Phase 1 Active not recruiting
NCT04843904 2026-01-07
SAVE
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT03198650 2025-10-09
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
AstraZeneca
Phase 1 Active not recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06547944 2024-08-09
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Active not recruiting